The Peptide Tier List: Separating Evidence from Hype
The Peptide Truth Files — Part 4 of 4
By now you understand the biological framework: GLP-1 RAs work and have the data, MOTS-c and humanin are the next frontier with a compelling PCOS story, and mitochondrial dysfunction ties it all together. What you need now is a clinical map of the full peptide landscape — honest, hierarchical, and built for physician decision-making.
This is not a list for recommending peptides to your patients. This is a list for understanding what your patients are already taking, asking about, or about to inject based on something they saw on Instagram.
The Regulatory Reality: February 2026
In February 2026, HHS Secretary Kennedy announced a reclassification: 14 peptides that had been moved to FDA Category 2 (restricted from compounding) in 2023–2024 are being moved back to Category 1 (legally compoundable with a physician prescription). This does NOT make these peptides FDA-approved drugs. It restores a legal pathway.
The five peptides remaining on Category 2 (restricted) include follistatin. The 14 being restored include BPC-157, TB-500, CJC-1295, ipamorelin, AOD-9604, MOTS-c, and others.
Reclassification does not mean safety or efficacy validation. The evidence requirements haven’t changed.
The Peptide Evidence Tier List
TIER 1 — PROVEN (FDA-Approved, Multiple Human RCTs)
Semaglutide (Ozempic/Wegovy)
Use: Weight loss, PCOS, T2DM, insulin resistance
Evidence: Multiple Phase 3 RCTs; PCOS meta-analyses 2024
Status: FDA-Approved
Tirzepatide (Mounjaro/Zepbound)
Use: Weight loss, T2DM; superior fat loss vs. semaglutide
Evidence: Phase 3 RCTs; SURMOUNT trials
Status: FDA-Approved
Tesamorelin (Egrifta)
Use: HIV lipodystrophy; off-label visceral fat reduction
Evidence: Phase 3 RCTs for HIV indication
Status: FDA-Approved
TIER 2 — EMERGING (Mechanistically Compelling, Limited Human Interventional Data)
MOTS-c
Use: Insulin resistance, metabolic syndrome, PCOS
Evidence: Strong animal data + PCOS human associational data (Scientific Reports, 2026)
Status: Category 1 Compounding (February 2026)
Humanin / HNG
Use: Insulin resistance, PCOS, ovarian dysfunction
Evidence: PCOS human associational data; animal model benefit
Status: Category 1 Compounding
CJC-1295 + Ipamorelin
Use: GH secretion, body composition
Evidence: Phase 2 level; limited PCOS-specific data
Status: Category 1 Compounding
TIER 3 — ANIMAL DATA ONLY (Mechanism Plausible, Human Evidence Absent)
BPC-157
Use: Tissue repair, gut healing, anti-inflammatory
Evidence: Robust animal data; minimal human trials; cancer signal concern
Status: Category 1 (restored February 2026)
⚠️ Cancer concern: promotes angiogenesis — relevant in oncology-risk populations
TB-500
Use: Wound healing, recovery
Evidence: Animal data; no human RCTs
Status: Category 1 (restored February 2026)
AOD-9604
Use: Fat loss, lipolysis
Evidence: One human trial in obesity; safety concerns previously cited by FDA
Status: Restored to Category 1 — use with extreme caution
TIER 4 — AVOID
Follistatin-344
Use: Muscle growth, myostatin inhibition
Evidence: Animal data only; remains Category 2 restricted
Status: PROHIBITED from compounding
Gray-market peptides (unverified sources)
Use: Anything marketed on social media
Evidence: None. 22% contamination/mislabeling rate on independent testing (Finnrick Analytics, 2025)
Status: Illegal for human therapeutic use. Often mislabeled, underdosed, or contaminated.
The Fraud Problem: What Your Patients Are Actually Buying
Independent testing by Finnrick Analytics found that 22% of commercially available peptide products fail quality control. The most common issue: dose divergence of more than 20% from the label. Underdosing wastes money. Overdosing injects unknown amounts of uncharacterized compounds.
U.S. customs data shows imports of hormone and peptide compounds hit $328 million in the first three quarters of 2025 — double the same period in 2024. Most come from China. Most are sold as “research chemicals” — a legal fiction that allows vendors to bypass prescription requirements while directly marketing to consumers.
The FDA issued warning letters to 30+ telehealth companies in 2024–2025 for inappropriately marketing compounded GLP-1s and other peptides. The gray market isn’t fringe. It’s mainstream.
The Cancer Concern: Specific to Your Patient Population
BPC-157 accelerates new blood vessel formation (angiogenesis) — which is how it promotes tissue healing. But angiogenesis is also how tumors recruit blood supply.
Your PCOS patients are at elevated risk for endometrial hyperplasia and endometrial cancer — the direct consequence of chronic anovulation and unopposed estrogen. They may also carry higher obesity-related breast cancer risk. Recommending or tacitly endorsing pro-angiogenic peptides without human safety data in this population is not appropriate. This is where your specialty knowledge should govern the conversation.
How to Have the Peptide Conversation With Your Patients
Ask first: “Are you taking any supplements, hormones, or peptides — including anything injected or prescribed through a telehealth company?”
Distinguish without dismissing: Acknowledge that GLP-1s are excellent, some peptides have real science behind them, and others have genuine risk. You are the guide, not the gatekeeper.
Assess the source: Is this an FDA-approved medication? A compounded product from a 503A or 503B licensed pharmacy with a physician’s prescription? Or a “research chemical” purchased online? Sourcing matters as much as the compound.
Apply population-specific risk: For PCOS women — reproductive age, possible periconception, elevated endometrial risk — the risk-benefit calculus is different than for a 40-year-old male athlete.
Own the Tier 1 conversation: Prescribe GLP-1 RAs appropriately. Monitor appropriately. Your patients won’t need to go to a wellness clinic for it if they can get it from you.
What to say to your patients: “Peptides are a real and rapidly evolving area of medicine. Some — like GLP-1 receptor agonists — have excellent data and I can prescribe them. Others are genuinely promising but not ready for clinical use. And a third category is being sold through influencers and online pharmacies with no quality control and no human safety data. My job is to help you understand which is which.”
Key Citations
FDA Peptide Reclassification February 2026. HHS/FDA Category 1/2 bulk drug substance list update.
CNN (April 2026). Peptides: what’s real, what’s risky, and what’s next.
Preprints.org (2025). Safety and Efficacy of Approved and Unapproved Peptide Therapies.
Finnrick Analytics (2025). Peptide quality testing data — 9,900 tests, 22% failure rate.
US Customs data (2025). Hormone and peptide compound imports: $328M in first 3Q 2025.
FDA Warning Letters (2024–2025). Telehealth companies marketing compounded peptides.
Precision Targeted Therapy for PCOS. Biomedicines, January 2026.
The Peptide Truth Files — Complete hweissmd on Substack | ProvationLife™ Herm Weiss, MD, MBA, FACOG
Medical Disclaimer
The information provided in this blog post and newsletter is for educational and informational purposes only. It does not constitute medical advice or professional services and should not be used to diagnose or treat any health problem or disease. Always seek the advice of your physician or other qualified health‑care provider regarding a medical condition. Never disregard professional medical advice or delay seeking it because of something you have read here.
Use of this content does not create a doctor–patient relationship. Individual responses to treatments and lifestyle changes can vary, and only your healthcare provider can evaluate your specific circumstances. If you are experiencing a medical emergency, call your local emergency services immediately.